Stock listing
Shanghai:600521 Zhejiang Huahai Pharmaceutical Co., Ltd. (华海药业) 股价
Follow Zhejiang Huahai Pharmaceutical Co., Ltd. into a list and get an email when it puts out news.
Share price · SSE:600521
¥15.56 CNY -0.92 (-5.6%)
Close on Nov 20, 2026
- Day range
- ¥15.45 – ¥16.32 CNYNov 20, 2026
- Volume
- 28.31M sharesNov 20, 2026
- Market cap
- ¥23.30B CNYAt the close on Nov 20, 2026 · price × 1.50B shares outstanding
- 52-week range
- ¥13.73 – ¥18.88 CNYLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ¥444.4M CNYMedian day 22.66M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SSE:600521 · CNY, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ¥15.56 | -0.92 | -5.6% | ¥16.16 | ¥16.32 | ¥15.45 | 28,308,800 | |
| ¥16.48 | -0.13 | -0.8% | ¥16.61 | ¥16.72 | ¥16.10 | 16,945,936 | |
| ¥16.61 | +0.09 | +0.5% | ¥16.45 | ¥16.79 | ¥16.35 | 13,800,333 | |
| ¥16.52 | -0.28 | -1.7% | ¥16.87 | ¥16.90 | ¥16.48 | 14,222,579 | |
| ¥16.80 | -0.26 | -1.5% | ¥16.98 | ¥17.09 | ¥16.70 | 17,353,382 | |
| ¥17.06 | -0.17 | -1.0% | ¥17.23 | ¥17.35 | ¥16.98 | 21,711,452 | |
| ¥17.23 | -0.10 | -0.6% | ¥17.29 | ¥17.41 | ¥17.18 | 16,717,457 | |
| ¥17.33 | +0.01 | +0.1% | ¥17.48 | ¥17.53 | ¥17.27 | 17,421,591 | |
| ¥17.32 | -0.29 | -1.6% | ¥17.66 | ¥17.82 | ¥17.28 | 21,262,548 | |
| ¥17.61 | -0.26 | -1.5% | ¥17.44 | ¥17.90 | ¥17.43 | 26,079,447 | |
| ¥17.87 | +0.89 | +5.2% | ¥16.92 | ¥17.93 | ¥16.92 | 53,216,681 | |
| ¥16.98 | +0.47 | +2.8% | ¥16.51 | ¥17.08 | ¥16.50 | 36,725,333 | |
| ¥16.51 | +0.01 | +0.1% | ¥16.50 | ¥16.69 | ¥16.31 | 18,210,807 | |
| ¥16.50 | +0.24 | +1.5% | ¥16.39 | ¥16.62 | ¥15.94 | 29,979,543 | |
| ¥16.26 | +0.36 | +2.3% | ¥15.85 | ¥16.72 | ¥15.66 | 34,449,194 | |
| ¥15.90 | -0.30 | -1.9% | ¥16.21 | ¥16.26 | ¥15.73 | 23,423,597 | |
| ¥16.20 | +0.17 | +1.1% | ¥16.15 | ¥16.39 | ¥16.06 | 19,556,308 | |
| ¥16.03 | -0.70 | -4.2% | ¥16.79 | ¥16.92 | ¥16.03 | 33,596,696 | |
| ¥16.73 | 0.00 | 0.0% | ¥16.65 | ¥16.96 | ¥16.60 | 21,324,378 | |
| ¥16.73 | +0.60 | +3.7% | ¥15.87 | ¥16.77 | ¥15.81 | 30,529,627 | |
| ¥16.13 | -0.51 | -3.1% | ¥16.59 | ¥16.59 | ¥16.13 | 25,461,033 | |
| ¥16.64 | -0.10 | -0.6% | ¥16.81 | ¥16.95 | ¥16.62 | 29,912,119 | |
| ¥16.74 | +0.08 | +0.5% | ¥16.60 | ¥16.78 | ¥16.40 | 25,083,208 | |
| ¥16.66 | +0.15 | +0.9% | ¥16.40 | ¥16.80 | ¥16.31 | 26,361,194 | |
| ¥16.51 | +0.02 | +0.1% | ¥16.67 | ¥17.19 | ¥16.34 | 40,090,352 | |
| ¥16.49 | -0.01 | -0.1% | ¥16.22 | ¥16.80 | ¥16.12 | 33,688,230 | |
| ¥16.50 | -0.37 | -2.2% | ¥16.80 | ¥16.81 | ¥16.39 | 27,416,595 | |
| ¥16.87 | -0.01 | -0.1% | ¥16.75 | ¥17.12 | ¥16.51 | 41,845,360 | |
| ¥16.88 | -0.57 | -3.3% | ¥17.49 | ¥17.49 | ¥16.86 | 41,711,422 | |
| ¥17.45 | +0.80 | +4.8% | ¥16.77 | ¥17.46 | ¥16.58 | 72,199,528 | |
| ¥16.65 | +0.31 | +1.9% | ¥17.00 | ¥17.10 | ¥16.56 | 61,239,685 | |
| ¥16.34 | +0.35 | +2.2% | ¥15.97 | ¥16.46 | ¥15.89 | 21,244,737 | |
| ¥15.99 | +0.08 | +0.5% | ¥15.91 | ¥16.38 | ¥15.82 | 18,838,722 | |
| ¥15.91 | +0.03 | +0.2% | ¥15.87 | ¥16.11 | ¥15.82 | 14,331,717 | |
| ¥15.88 | -0.53 | -3.2% | ¥16.22 | ¥16.43 | ¥15.75 | 27,338,946 | |
| ¥16.41 | -0.16 | -1.0% | ¥16.50 | ¥16.63 | ¥16.33 | 17,316,859 | |
| ¥16.57 | -0.09 | -0.5% | ¥16.61 | ¥16.75 | ¥16.45 | 21,793,719 | |
| ¥16.66 | +0.52 | +3.2% | ¥16.18 | ¥16.71 | ¥16.18 | 34,973,650 | |
| ¥16.14 | -0.21 | -1.3% | ¥16.35 | ¥16.56 | ¥16.13 | 18,886,806 | |
| ¥16.35 | +0.14 | +0.9% | ¥16.10 | ¥16.60 | ¥16.09 | 22,398,747 | |
| ¥16.21 | +0.69 | +4.4% | ¥15.63 | ¥16.42 | ¥15.45 | 36,491,509 | |
| ¥15.52 | -0.10 | -0.6% | ¥15.51 | ¥15.65 | ¥15.47 | 10,148,015 | |
| ¥15.62 | +0.25 | +1.6% | ¥15.36 | ¥15.65 | ¥15.29 | 13,957,462 | |
| ¥15.37 | -0.17 | -1.1% | ¥15.51 | ¥15.59 | ¥15.15 | 15,770,288 | |
| ¥15.54 | -0.34 | -2.1% | ¥15.78 | ¥15.87 | ¥15.45 | 17,899,325 | |
| ¥15.88 | -0.01 | -0.1% | ¥15.81 | ¥15.93 | ¥15.74 | 11,067,222 | |
| ¥15.89 | +0.14 | +0.9% | ¥15.81 | ¥16.02 | ¥15.66 | 14,663,744 | |
| ¥15.75 | -0.24 | -1.5% | ¥15.96 | ¥15.96 | ¥15.63 | 19,306,424 | |
| ¥15.99 | -0.12 | -0.7% | ¥16.10 | ¥16.17 | ¥15.96 | 18,587,700 | |
| ¥16.11 | +0.14 | +0.9% | ¥15.97 | ¥16.15 | ¥15.84 | 17,100,759 | |
| ¥15.97 | -0.23 | -1.4% | ¥16.14 | ¥16.24 | ¥15.96 | 19,713,846 | |
| ¥16.20 | +0.09 | +0.6% | ¥16.10 | ¥16.27 | ¥16.01 | 21,896,005 | |
| ¥16.11 | -0.35 | -2.1% | ¥16.35 | ¥16.35 | ¥15.93 | 27,485,883 | |
| ¥16.46 | -0.18 | -1.1% | ¥16.60 | ¥16.67 | ¥16.33 | 21,897,987 | |
| ¥16.64 | +0.24 | +1.5% | ¥16.44 | ¥16.88 | ¥16.41 | 32,167,729 | |
| ¥16.40 | -0.03 | -0.2% | ¥16.36 | ¥16.66 | ¥16.20 | 22,921,084 | |
| ¥16.43 | +0.23 | +1.4% | ¥16.08 | ¥16.45 | ¥15.88 | 28,734,377 | |
| ¥16.20 | -0.42 | -2.5% | ¥16.51 | ¥16.66 | ¥15.90 | 36,500,123 | |
| ¥16.62 | -0.75 | -4.3% | ¥17.06 | ¥17.10 | ¥16.48 | 50,559,380 | |
| ¥17.37 | +0.22 | +1.3% | ¥17.50 | ¥17.93 | ¥17.17 | 56,253,772 |
Splits
9 splits since 2004 · SSE:600521 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 11-for-10 | Split | |
| 6-for-5 | Split | |
| 13-for-10 | Split | |
| 13-for-10 | Split | |
| 6-for-5 | Split | |
| 3-for-2 | Split | |
| 13-for-10 | Split | |
| 13-for-10 | Split | |
| 9-for-5 | Split |
- Ticker
- Shanghai:600521
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Shanghai
- Currency
- CNY
What changed lately
Latest news release · Nov 6, 2026
(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Progress in Providing Guarantee for Subsidiary
Latest news
(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Progress in Providing Guarantee for Subsidiary
Nov 6, 2026
Closed ¥17.61 (-1.5%) on Nov 6, 2026
(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Results of Redemption at Maturity of "HUAHAI Convertible Bonds" and Share Changes
Nov 3, 2026
Closed ¥16.51 (+0.1%) on Nov 3, 2026
(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Obtaining Approval for Drug Clinical Trials by Subsidiary
Nov 3, 2026
Closed ¥16.51 (+0.1%) on Nov 3, 2026
(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Report for Q3 2026
Oct 30, 2026
Closed ¥16.26 (+2.3%) on Oct 30, 2026
(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 18th Extraordinary Meeting of the 9th Board of Directors
Oct 30, 2026
Closed ¥16.26 (+2.3%) on Oct 30, 2026
(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Provision for Asset Impairment for the First Three Quarters of 2026
Oct 30, 2026
Closed ¥16.26 (+2.3%) on Oct 30, 2026
(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Redemption at Maturity and Delisting of "HUAHAI Convertible Bonds"
Oct 23, 2026
Closed ¥16.73 (+3.7%) on Oct 23, 2026
(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Obtaining Drug Registration Certificate
Oct 20, 2026
Closed ¥16.74 (+0.5%) on Oct 20, 2026
Zhejiang Huahai Pharmaceutical Co., Ltd. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 70 in the last 12 months · 76 in all · newest Nov 6, 2026 · oldest 2025
Valuation
P/E 24.6× against a median of 17.4×: 8th lowest of 10 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- ¥24.34B CNY
- P/E
- 24.6×
- EV/sales
- 2.5×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 2.3×
- Gross margin
- 58.7%
- Operating margin
- 15.5%
- Net margin
- 9.8%
- Debt to equity
- 0.3×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Zhejiang Huahai Pharmaceutical Co., Ltd. Class A · SSE:600521 | US$3.49B | US$3.65B | 24.6× | 2.5× | n/a | 2.3× | 9.8% | 0.3× | n/a |
| Shijiazhuang Yiling Pharmaceutical Co., Ltd. Class A · SZSE:002603 | US$3.72B | US$3.34B | 18.0× | 2.8× | n/a | 2.2× | 17.4% | 0.0× | n/a |
| Organon & Co. · NYSE:OGN | US$3.65B | US$10.75B | 17.1× | 1.8× | n/a | 3.1× | 3.5% | 7.2× | 0.52 |
| Tarsus Pharmaceuticals, Inc. · NASDAQ:TARS | US$3.60B | US$3.36B | n/a | 4.9× | n/a | 34.6× | −102.9% | 0.7× | 0.62 |
| Laboratorios Farmaceuticos Rovi, S.A. · BME:ROVI | US$3.54B | US$3.52B | 17.4× | 4.2× | 15.8× | 4.6× | 23.9% | 0.1× | n/a |
| China Resources Pharmaceutical Group Ltd. · HKEX:3320 | US$3.51B | US$14.02B | 5.2× | 0.3× | 5.1× | 0.4× | 1.5% | 1.9× | n/a |
| Orion Oyj Class A · OMXHEX:ORNAV | US$3.42B | US$3.40B | 4.7× | 1.4× | 3.5× | 2.2× | 30.3% | 0.1× | n/a |
| Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A · SZSE:002262 | US$3.41B | US$2.79B | 20.8× | 3.0× | n/a | 2.6× | 17.7% | 0.0× | n/a |
| Beijing Tiantan Biological Products Corporation Limited Class A · SSE:600161 | US$3.39B | US$3.10B | 32.3× | 3.7× | n/a | 1.9× | 12.6% | 0.0× | n/a |
| Arcutis Biotherapeutics, Inc. · NASDAQ:ARQT | US$3.33B | US$3.18B | 111× | 6.3× | 85.1× | 13.7× | 5.9% | 0.5× | 1.38 |
| Simcere Pharmaceutical Group Limited · HKEX:2096 | US$3.32B | US$3.08B | 16.5× | 2.7× | 10.6× | 2.4× | 17.4% | 0.3× | n/a |
| Median of the others | US$3.47B | US$3.35B | 17.4× | 2.9× | 10.6× | 2.5× | 15.0% | 0.2× | 0.62 |
Forecasts
Analysts' consensus from EODHD, read Nov 21, 2026. Not 6ix's view and not investment advice.
- Price target
- 19.67 CNY · Analysts' mean
- EPS, year to Dec 2026
- 0.92 · 1 analyst
- Revenue, year to Dec 2026
- 9.74B · 1 analyst
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2026 | Aug 26, 2026 · After close | +1.5% |
| Q1 2026 | Apr 29, 2026 · After close | +1.8% |
| Q2 2025 | Aug 25, 2025 · After close | −1.3% |
| Q1 2025 | Apr 29, 2025 · After close | −0.2% |
| Q3 2024 | Oct 30, 2024 · After close | −0.9% |
| Q1 2024 | Apr 29, 2024 · After close | +4.0% |
| Q3 2023 | Oct 30, 2023 · After close | +0.4% |
| Q2 2023 | Aug 30, 2023 · After close | −0.5% |
| Q1 2023 | Apr 28, 2023 · Before open | +0.1% |
| Q3 2022 | Oct 28, 2022 · Before open | −2.5% |
All 15 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2022 | Aug 30, 2022 · After close | +0.3% |
| Q1 2022 | Apr 18, 2022 · Before open | −1.6% |
| Quarter to Sep 30, 2021 | Oct 29, 2021 · Before open | −0.4% |
| Quarter to Jun 30, 2021 | Aug 26, 2021 · After close | −1.7% |
| Quarter to Mar 31, 2021 | Apr 25, 2021 · Before open | +10.0% |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.59B | 9.55B | 8.31B | 8.27B | 6.64B | 6.49B | 5.39B | 5.09B | 5.00B | 4.09B |
| Cost of revenue | 3.42B | 3.74B | 3.38B | 3.18B | 2.67B | 2.38B | 2.20B | 2.14B | 2.20B | 2.05B |
| Gross profit | 5.17B | 5.81B | 4.93B | 5.09B | 3.97B | 4.10B | 3.19B | 2.95B | 2.80B | 2.04B |
| Research and development | 1.23B | 986.7M | 983.0M | 925.5M | 942.3M | 565.7M | 467.4M | 396.8M | 353.4M | 364.0M |
| Selling, general and administrative | 2.11B | 1.46B | 1.30B | 1.29B | 1.27B | 1.08B | 895.6M | 839.8M | 646.6M | 852.9M |
| Operating income | 833.5M | 1.47B | 1.12B | 1.55B | 868.4M | 1.29B | 824.4M | 475.2M | 791.2M | 508.0M |
| Depreciation and amortization | 1.01B | 916.8M | 789.6M | 672.0M | 563.1M | 470.8M | 410.7M | 345.0M | 289.9M | 251.0M |
| EBITDA | 1.84B | 2.39B | 1.91B | 2.22B | 1.43B | 1.76B | 1.24B | 820.3M | 1.08B | 759.0M |
| Interest expense | 233.6M | 226.1M | 237.8M | 223.9M | 170.7M | 139.1M | 234.9M | 150.4M | 65.2M | 45.4M |
| Income before tax | 443.9M | 1.46B | 1.10B | 1.51B | 786.9M | 1.22B | 760.9M | 157.2M | 779.2M | 567.1M |
| Income tax | 356.1M | 283.1M | 332.9M | 306.3M | 220.8M | 154.0M | 22.3M | 155.7M | 110.2M | |
| Net income | 266.4M | 1.12B | 830.5M | 1.17B | 487.5M | 929.8M | 569.6M | 107.5M | 639.2M | 500.8M |
| Earnings per share, basic | 0.18 | 0.77 | 0.57 | 0.80 | 0.34 | 0.64 | 0.39 | 0.08 | 0.46 | 0.37 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.50B | 1.54B | 1.34B | 1.37B | 1.88B | 2.21B | 1.50B | 910.8M | 691.3M | 791.6M |
| Short-term investments | 76.0M | 60.8M | 93.0M | 143.1M | 1.01M | 2.05K | ||||
| Receivables | 2.87B | 3.27B | 2.68B | 2.83B | 1.91B | 1.76B | 1.40B | 1.94B | 1.66B | 1.35B |
| Inventory | 3.71B | 3.41B | 3.43B | 3.37B | 2.74B | 2.37B | 2.22B | 2.18B | 1.59B | 1.33B |
| Current assets | 8.74B | 8.48B | 7.62B | 7.91B | 6.81B | 6.52B | 5.27B | 5.21B | 4.07B | 3.51B |
| Property, plant and equipment | 5.96B | 4.37B | 3.80B | 3.52B | 2.94B | 2.56B | ||||
| Goodwill | 64.4M | 64.4M | 64.4M | 70.9M | 70.9M | 70.9M | 70.9M | 70.9M | 70.9M | 70.9M |
| Total assets | 21.5B | 20.3B | 18.6B | 18.2B | 15.5B | 13.0B | 10.7B | 10.4B | 8.27B | 6.73B |
| Accounts payable | 1.81B | 1.59B | 1.39B | 1.20B | 881.8M | 392.5M | 577.0M | 662.6M | 759.4M | 175.3M |
| Current liabilities | 9.11B | 5.98B | 5.45B | 4.80B | 4.24B | 2.89B | 3.36B | 4.77B | 2.84B | 1.51B |
| Long-term debt | 1.84B | 4.39B | 4.02B | 4.64B | 3.50B | 2.92B | 1.18B | 900.0M | 222.2M | 534.7M |
| Total debt | 6.52B | 5.65B | 6.86B | 5.63B | 4.05B | 3.31B | 3.55B | 1.81B | 1.02B | |
| Total liabilities | 12.0B | 11.2B | 10.3B | 10.4B | 8.69B | 6.27B | 4.95B | 6.16B | 3.21B | 2.15B |
| Shareholders' equity | 9.44B | 8.90B | 8.08B | 7.55B | 6.56B | 6.51B | 5.61B | 4.07B | 4.88B | 4.38B |
| Shares outstanding | 1.50B | 1.45B | 1.46B | 1.46B | 1.45B | 1.45B | 1.45B | 1.31B | 1.38B | 1.35B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1.23B | 2.17B | 2.22B | 1.24B | 938.4M | 1.56B | 1.75B | 67.9M | 546.2M | 433.1M |
| Capital spending | -1.97B | -1.85B | -1.59B | -2.32B | -2.43B | -1.28B | -794.3M | -1.12B | -794.5M | -732.9M |
| Free cash flow | -736.0M | 319.3M | 624.6M | -1.07B | -1.50B | 279.0M | 959.6M | -1.06B | -248.3M | -299.8M |
| Cash from investing | -1.92B | -1.62B | -2.43B | -2.36B | -1.36B | -791.1M | -1.26B | -1.14B | -706.7M | |
| Cash from financing | -132.9M | -644.2M | 609.0M | 1.12B | 596.3M | -400.3M | 1.35B | 556.6M | 408.8M | |
| Dividends paid | -546.2M | -475.4M | -556.0M | -147.3M | -290.9M | -392.8M | -208.9M | -308.0M | -241.6M | -194.4M |
| Share buybacks | -189.9M | -71.0M | -172.4M | -150.0M | -4.75M | |||||
| Change in cash | -31.0M | 170.6M | -21.0M | -526.2M | -343.6M | 708.9M | 591.3M | 219.6M | -74.1M | 185.9M |
Filings
All 76 filings
Cap table
Built by 6ix from Zhejiang Huahai Pharmaceutical Co., Ltd. Class A’s releases
- Common shares
- 1,497,253,704
- Fully diluted
- 1,497,253,704
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,497,253,704 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,497,253,704 |
Log in to ask 6ix AI your own questions about Zhejiang Huahai Pharmaceutical Co., Ltd.